

**2HDC02**

**TIME: 13:00 – 16:15**

**COURSE TITLE: MULTIPLE SCLEROSIS II**

**CREDIT: 2 CREDITS**

**1-RECOMMENDED FOR: NEUROLOGY RESIDENTS AND SPECIALISTS, ACADEMICS**

**2-OBJECTIVE OF THE COURSE:**

The overall objective of this course is to discuss the current developments in the treatment of MS and NMO/NMO spectrum diseases and provide an up-to-date perspective to current treatment algorithms. Treatment approach to NMO/NMO spectrum diseases, role of injectable IM medications in MS treatment; oral medications in MS treatment, their role, treatment method, Monoclonal antibodies; treatment modalities in MS will be discussed. Treatment switch in multiple sclerosis; how we should proceed for which patient, and current data about the treatment and pharmacogenetics in multiple sclerosis will be discussed.

**3-WHAT WILL BE THE LEARNING OUTCOMES THAT THE PARTICIPANTS WILL ACQUIRE AT THE END OF THE COURSE?**

Participants of this course will acquire relevant knowledge and experience about injectable treatments in MS, oral therapies, monoclonal antibody treatments and changing treatment algorithms and practices of treatment switch in MS. In addition, they will be informed of the treatments for NMO/NMO spectrum diseases and pharmacogenetics of MS treatment.

**4-PARTICIPANTS ARE EXPECTED TO: LISTEN, SHARE THEIR EXPERIENCES, GET ACTIVELY INVOLVED IN DISCUSSIONS**

**5-COURSE PROGRAM**

**Session Title: Current Developments in the Treatment of MS/NMO; Current State of Treatment Algorithms**

**Moderators:**

Sabahattin Saip (İstanbul University Cerrahpaşa - Cerrahpaşa Faculty of Medicine, Neurology Dpt.)  
Sibel Canbaz Kabay (Kütahya Sağlık Bilimleri University Faculty of Medicine, Neurology Dpt.)

**Speakers and Topics:**

- Treatment Approach in NMO/NMO Spectrum Diseases  
Nur Yüceyar  
(Ege University Faculty of Medicine, Neurology Dpt.)
- Role of Injectable Immunomodulatory Therapies in MS Treatment  
Serkan Özakbaş  
(Dokuz Eylül University Faculty of Medicine, Neurology Dpt.)
- Oral Therapies; Its Role in MS Treatment, Treatment Modality  
Yeşim Beckmann  
(İzmir Katip Çelebi University Atatürk Training and Research Hospital, Neurology Clinic)

**BREAK (15 Minutes)**

- Monoclonal Antibodies; Treatment Modality in MS Treatment  
Ömer Faruk Turan  
(Uludağ University Faculty of Medicine, Neurology Dpt.)
- Switching Treatment in Multiple Sclerosis; How to Proceed for Which Patient?  
Cavit Boz

(Karadeniz Technical University Faculty of Medicine, Neurology Dpt.)

- Treatment and Pharmacogenetics of Multiple Sclerosis

Taşkın Duman

(Mustafa Kemal University Faculty of Medicine, Neurology Dpt.)

- Discussion